Aktienanalyse zu Jyong Biotech Ltd (MENS)MENSJyong Biotech Ltd

Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer. It operates in the Healthcare sector.

Currently, Jyong Biotech Ltd (MENS) is not a strong buy. The stock is trading at $1.87, which is near its 52-week low of $1.43, indicating significant downside risk. The RSI is at 46.062, suggesting it is neither overbought nor oversold, but the stock has a year-to-date change of -45.16%, reflecting ongoing struggles. Additionally, the company has reported substantial losses, with a net income of -3,419,000 USD for Q4 2025, which raises concerns about its financial health. The main risk is the high volatility, with a historical volatility of 80.78%, making it a risky investment for long-term holders.